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We have recently shown that a single injection of mature, antigen-pulsed,
human dendritic cells (DCs) rapidly elicits CD4+ and CD8+ T-cell immunity
in vivo. The DCs were pulsed with 2 foreign proteins, keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), as well as an HLA A2.1-restricted
influenza matrix peptide (MP). Responses to all 3 antigens peaked at 30–90
days after immunization and declined thereafter. To determine if the foreign
helper proteins (TT and KLH) were essential for CD8+ T-cell responses to the
viral peptide, we reinjected 3 of the HLA-2.1 subjects with mature DCs pulsed
with MP alone. All 3 volunteers showed a rapid boost in MP-specific immunity, and freshly sampled blood from 1 contained cytolytic T cells. In all 3 subjects, CD8+ T-cell responses to booster DCs were faster and of greater magnitude than the responses to the first DC injection. Importantly, the T cells that
proliferated after booster DC treatment secreted interferon-γ upon challenge
with much lower doses of viral peptide than those elicited after the first injection, indicating a higher functional avidity for the ligand. These data begin to
outline the kinetics of T-cell immunity in response to DCs and demonstrate
that booster injections of mature DCs enhance both qualitative and quantitative aspects of CD8+ T-cell function in humans.
This article may have been published online in advance of the print edition. The date of publication is available from the JCI website, http://www.jci.org.
J. Clin. Invest. 105:R9–R14 (2000).

Introduction
Although several approaches (such as
DNA vaccines, viral vectors) generate
protective T-cell immunity in mice, it has
proven difficult to generate potent T-cell
immunity in humans with current vaccines (1). Dendritic cells (DCs), nature’s
adjuvant, are antigen-presenting cells
(APCs) specialized to initiate T-cell
immunity (2). It is known that exposure
to inflammatory stimuli leads to terminal differentiation or maturation of
DCs, with enhanced capacity to stimulate T-cell immunity (2). We have shown
recently that a single injection of antigen-bearing, monocyte-derived, mature
DCs leads to rapid enhancement of Tcell responses in humans (3). These data
demonstrated that mature DCs are
potent immune adjuvants in humans
and provided the first controlled evidence of their immunogenicity.

More quantitative T-cell assays
have now made it possible to study
the kinetics and longevity of the Tcell immune response in humans
after DC immunization. In previous
work, serial quantitative measurements of immune parameters were
not performed (4, 5). Here we serially
characterize the kinetics and durability of CD4+ and CD8+ T-cell responses after DC injection in humans
using a panel of quantitative assays.
We also show that a booster injection
of mature DCs leads to greater and
more rapid enhancement of the
CD8+ T-cell response without the
need for “foreign helper epitopes.”
Importantly, we demonstrate that T
cells elicited after booster DCs are
functionally superior and recognize
lower doses of antigen than those
elicited after the first injection.
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Methods
Study subjects

Seven of 9 subjects who were injected
with antigen-pulsed DCs in the initial
study (3) were available for long-term
monitoring and are subjects of the
present analysis. Two subjects (P2, P3)
had left the New York area and were
unavailable for follow-up.
Schema for immune monitoring and
booster injections

All subjects were monitored for
immune responses to study antigens
every 1–4 months after the first antigen-pulsed DC injection. In 3 of 4
HLA A2.1+ subjects (P4, P5, P6), booster DC injections were performed at
7–9 months after the first antigenpulsed injection. A booster injection
was not considered in the fourth HLA
A2.1+ subject (P1) because of intervening pregnancy. All subjects who
received a booster injection signed an
updated informed consent. Subjects
were monitored 2 days, 1 week, 1
month after the booster and every 1–4
months thereafter. The study was
approved by the Rockefeller University Institutional Review Board and the
U.S. Food and Drug Administration.
Measurement of immune responses

Antigen-specific proliferation. Antigenspecific proliferation to keyhole limpet
hemocyanin (KLH), tetanus toxoid
(TT), and staphylococcal enterotoxin
A (SEA) as a control, was performed as
described earlier (3). All assays were
performed on fresh PBMCs. When
possible, cryopreserved samples from
before and after immunization were
also thawed and assayed together. In
R9

some cultures, the phenotype of the
responding T cells was monitored at
the end of culture by staining for CD4
and quantifying the percentage of
CD4+ T-cell blasts (high forward scatter) using flow cytometry.
Enzyme-linked immunospot assay for
IFN-γ release from single antigen-specific T
cells. Enzyme-linked immunospot
(ELISPOT) assay for detection of
influenza matrix protein peptide
(MP) and influenza-specific T cells
was performed as described earlier on
freshly isolated PBMCs (3). To assess
the peptide sensitivity of antigen-specific T cells, pre- and postimmunization specimens were thawed together
and cocultured overnight (16 hours)
with freshly generated autologous
mature DCs pulsed with graded doses
(0.01–100 ng/mL) of MP (unpulsed
DCs as control) at a DC/T cell ratio of
30:1. The number of antigen-specific
IFN-γ–producing cells was quantified
as noted above.
Bulk cytolytic effector assays. For detection of MP-specific killers in bulk
uncultured PBMCs, freshly isolated
PBMCs were directly added to labeled
T2 targets pulsed with 1 µM MP
(unpulsed T2 as controls).
T-cell recall assays for bulk cytolytic effectors
and IFN-γ–secreting cells. Recall T-cell
memory was quantified using 2
methodologies, ELISPOT and cytolytic
effector (CTL) assay. Recall CTL assay
was performed as described earlier,
using antigen-pulsed DCs pulsed with
MP (1 µM) or infected with live influenza virus (moi = 2) (3). For recall
ELISPOT assay, pre- and postimmunization specimens were thawed together and cocultured with freshly generated mature DCs pulsed with MP (versus
no peptide as control) as in the recall
CTL assay. After 7 days, cells were transferred to an ELISPOT plate at 105 cells
per well and cultured for 14–18 hours
with or without restimulation with MP.
Generation of dendritic cells

DCs were generated from blood
monocyte precursors and maturation
was induced by culture in monocyteconditioned medium as described (3).
Booster DC injection

DCs were pulsed overnight 1 day
before injection with 1 µM HLA
R10

A*0201–restricted influenza MP (manufactured under Good Laboratory
Practice [GLP] by Alan Houghton,
Sloan Kettering Cancer Center, New
York, New York, USA). On the day of
injection, the DCs were resuspended in
normal saline containing 5% autologous plasma and injected as a superficial subcutaneous. injection as
described earlier (3). All injected DC
preparations tested negative for bacterial and fungal contamination.
Detection of KLH-specific antibodies

KLH-specific antibodies were detected
by an ELISA adapted from methods
described by Holtl et al. (6). Quantitation was performed by subtracting OD
(450 nm) in KLH wells from that in control wells. Pre- and postimmunization
sera from each volunteer were assayed
together, and all experiments included a
positive control serum known to contain high-titer KLH-specific antibodies.
Statistical analysis

For comparison of the immune
response between first and booster DC
injections, ratios of pre- and postimmunization values were compared by
paired t test after logarithmic transformation of the data. P values less than
0.05 were considered significant.

Results
Longevity of KLH and TT-specific T-cell
responses. All 9 subjects injected with
KLH-pulsed DCs showed priming of
KLH-specific immune response (3).
T-cell proliferative responses to KLH
peaked at a median of 30 days (range
30–90 days) after antigen-pulsed DC
injection and declined thereafter
(Figure 1a). However, at ≥ 6 months
after the DC injection, proliferative
responses to KLH were still
detectable above baseline in 4 of 7
(P1, P5, P6, P9) subjects. Five of 6
subjects (P2, P4, P5, P7, P9) injected
with TT-pulsed DCs had boosting of
TT-specific immunity (3). TT-specific T-cell response also peaked at a
median of 30 days after injection and
then declined, but remained
detectable above baseline at ≥ 6
months in 2 (P5, P7) of 4 responding
(P4, P5, P7, P9) subjects available for
follow-up (Figure 1b). In the 3 subjects not injected with TT-pulsed
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DCs, as well as those injected with
antigen alone, there was no significant change in TT-specific responses
during follow-up (data not shown).
Injection of booster DCs (P4, P5, P6)
that were pulsed with MP only also
did not lead to a nonspecific increase
in KLH- or TT-specific immunity.
To further confirm that the differences between baseline measurements
and ≥ 6-month postimmunization
time points were not because of
interassay variability, samples from
these time points, when possible, were
thawed and assayed together. Data
from a representative volunteer (P5)
are shown (Figure 1, c and d). The CD4
nature of the proliferative response in
these cultures and the frequency of
responding cells was also evident when
we monitored T-cell phenotype and
proportion of CD4 T-cell blasts (high
forward scatter) using flow cytometry
(Figure 1e). The maximum number of
CD4 T blasts was detected at 30 days
after immunization, consistent with
the data from proliferation assays on
both fresh and thawed cells. We
showed previously that KLH and TT
responses to antigen-pulsed DCs were
CD4 dependent (3).
Development of KLH-specific humoral
immunity. Sera from before immunization and 3 months after immunization were examined for the presence of KLH-specific antibodies in 7
volunteers injected with KLH-pulsed
DCs (P1, P4–P9) and those injected
with KLH alone (A1–A4). KLH-specific antibody responses (at much lower
titer than our positive control serum),
were detected in 3 of 4 volunteers
injected with KLH alone (Figure 1, f
and g). In contrast, KLH-specific antibodies were detected in only 1 (P4) of
7 subjects tested who received KLHpulsed DCs, and these were at similarly low titer.
Durability of MP-specific T-cell immunity after the first antigen-pulsed DC injection. Circulating MP-specific IFNγ–producing CD8+ T cells peaked at a
median of 60 days (range 7–90) after
DC injection. In 3 of 4 HLA A 2.1+
volunteers (P4, P5, P6), the number
of circulating MP-specific CD8+ T
cells declined back to baseline over
the next 3–6 months (Figure 2, a–c).
However, in 1 volunteer (P1; Figure

Figure 1
TT- and KLH-specific immunity after DC injection. (a) Longevity of KLH-specific immune response after single DC injection. For each measurement shown, 105 freshly isolated PBMCs were incubated in the presence or absence of 10 µg/mL KLH for 5 days, and proliferation was
measured as 3H-TdR incorporation. Results are expressed as stimulation index. SEM < 30%; cpm without antigen < 5 × 103. (b) Longevity of
TT-specific immune response after single DC injection. For each measurement shown, 105 freshly isolated PBMCs were incubated in the presence or absence of 3 µg/mL TT for 5 days, and proliferation was measured as 3H-TdR incorporation. Results are expressed as stimulation
index. SEM < 30%. (c) Evaluation of longevity of KLH-specific response using cryopreserved specimens. Pre- and postimmunization specimens
were thawed together and cultured in the presence or absence of 10 µg/mL KLH for 5 days. Antigen-specific proliferation was measured as
3H-TdR incorporation. Results are shown as stimulation index. Data shown are for 1 subject (P5), representative of 3 subjects tested. (d) Evaluation of longevity of TT- specific response using cryopreserved specimens. Pre- and postimmunization specimens were thawed together and
cultured in the presence or absence of 3 µg/mL TT for 5 days. Antigen-specific proliferation was measured as 3H-TdR incorporation. Results
are shown as stimulation index. Data shown are for 1 subject (P5), representative of 2 subjects tested. (e) Quantification of CD4 proliferative
response as percent of CD4 blasts. T-cell cultures from the experiment in c and d were stained for CD4 and analyzed by flow cytometry. Percent of CD4 blasts were quantified as percent of CD4+ T cells with high forward scatter, noted in the upper-right quadrant. Data shown are
gated for CD4+ cells. (f and g) Detection of KLH-specific antibodies. (f) Presence of KLH-specific antibodies was determined in sera before
and 3 months after immunization by ELISA as described in Methods. Data shown are at a serum dilution of 1:104. Because of variable background, reactivity was assayed by comparing pre- and postimmunization samples in the same individual. All assays were repeated to verify
results. *P < 0.05. (g) Representative data from a subject (A1) injected with KLH alone. KLH-specific antibodies were detected in only 1 of 7
volunteers (P4) injected with KLH-pulsed DCs. Positive control was an individual with known high-titer anti-KLH antibodies.
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Figure 2
Enhancement of antigen-specific CD8+ T cells in vivo. (a–d) Kinetics of antigen-specific CD8+ T cells following DC injection(s). MP-specific
interferon-γ–producing T cells in freshly isolated uncultured T cells were quantified using an ELISPOT assay (triangles). Results are shown
as the number of spot-forming cells (SFC)/2 × 105 PBMC. MP-specific CTLs were quantified after 7-day coculture with MP-pulsed mature
DCs (DC/T cell ratio 30:1). Data shown are percent of MP-specific lysis at each time point (effector/target [E/T] ratio 20:1) after subtracting
lysis with unpulsed T2 targets and that using unpulsed DCs (circles). SEM < 25%. Arrows indicate the timing of DC injections. The subjects
were: a, P4; b, P5; c, P6; and d, P1. (e) Detection of circulating lytic effectors after booster DC injection. Freshly isolated bulk PBMCs of a
study subject (P4) from before injection and 7 days after booster DC injections 1 and 2 were directly tested for the presence of MP-specific
lytic effectors using MP-pulsed T2 cells as targets at varying E/T ratios. Data shown are percent of MP-specific lysis after subtracting lysis of
unpulsed T2 cells. (f) Enhancement of MP-specific IFN-γ–producing T cells after booster DC injection, recall ELISPOT assay. Cryopreserved
PBMCs from before (pre) and 30 or 120 days after booster DC injection were thawed together and cocultured for 7 days with freshly generated mature DCs (DC/PBMC ratio 1:30), either unpulsed, DC(–), or pulsed with 1 µg/mL MP, DC (MP), without exogenous cytokines.
On day 7, T cells were either left unstimulated or restimulated by the addition of 10 µg/mL MP peptide and transferred to an ELISPOT plate.
MP-specific IFN-γ–producing T cells were quantified using a 16-hour ELISPOT assay. SEM < 30%.

2d), the number of MP-specific T
cells leveled off at a higher level.
When T cells were boosted in culture
with autologous DCs, there was an
increase in MP-specific lytic effectors
after immunization in 3 of 4 subjects
(P1, P5, P6; Figure 2, a–d). In these 3
subjects, the response peaked at a
mean of 70 days (range 30–90 days)
after injection (Figure 2, b–d). Similar
to the ELISPOT assay, MP-specific
recall CTL responses had returned
back to baseline by 6 months after the
first injection in 3 of 4 subjects.
Booster DC injection: toxicity. All 3 HLA
A2.1+ subjects with declining circulating MP-specific T cells (P4, P5, P6)
were boosted with mature DCs pulsed
R12

with MP alone. The dose of booster
DCs was 4.5–5 × 106 cells, and purity
ranged from 39–74%. KLH and TT
were omitted from booster DCs to
determine if these epitopes were
required for eliciting MP-specific
CD8+ T-cell responses using mature
DCs. All booster injections were well
tolerated with no greater than grade 1
toxicity or evidence of autoimmunity.
Local reaction to DC injection. Two of 3
subjects developed a local reaction at
the injection site. In these 2 subjects
these reactions were larger and developed earlier (at 24 versus 48 hours), as
compared with those after the first
injection (data not shown).
T-cell response to booster DC injections:
The Journal of Clinical Investigation

|

Volume 105

assays on uncultured PBMCs. All 3 subjects who received a booster DC injection had an increase in the number of
circulating MP-specific IFN-γ–producing T cells in freshly isolated PBMCs
(Figure 2, a–c). This response was evident as early as 2 days after the injection in 2 subjects and by 7 days in all
subjects. Immune response to booster
injection was more rapid, with mean
18.4-fold increase in MP-specific T cells
in the first week, compared with 4.8fold increase after the first injection (P
= 0.01). In addition, the peak responses
following booster DCs were higher
than those after the first injection
(19.7-fold versus 7-fold; P = 0.008). As
with the first injection, increase in MP-

specific IFN-γ–producing T cells after
booster DCs in 2 subjects with longer
follow-up (P5, P6) has not been sustained and has declined back to preinjection baseline within 6 months.
Increased peptide sensitivity of the expanded CD8+ T-cell response. We were unable to
detect cytolytic effectors in bulk uncultured T cells in any of the subjects after
the first DC injection. However, bulk
lytic effectors were detected after booster DCs in 1 of 3 subjects 7 days after
injection (P4; Figure 2e). The detection
of bulk lytic effectors in this subject (and
not in others) could not be explained
simply by the frequency of MP-specific
IFN-γ–producing T cells. Therefore, we
next examined peptide sensitivity of
elicited T-cell populations as a measure
of functional maturation of the
immune response. To control for variable thawing of resident APCs in these
samples, freshly prepared autologous
mature DCs pulsed with various doses
of peptides were used as APCs in a 16hour ELISPOT assay for IFN-γ–secreting
cells with thawed uncultured PBMCs
from 30 days after the first MP-pulsed
DC immunization or booster DCs. T
cells elicited after booster DCs demonstrated greater peptide sensitivity than
those after the first injection in all 3 subjects. Remarkably, T cells in P4 (who
developed circulating lytic effectors),
showed the greatest peptide sensitivity,
with half-maximal recognition at less
than 0.01 ng/mL (Figure 3).
T-cell response to booster DCs: assays in cultured T cells. When T cells were boosted
in culture with peptide-pulsed DCs,
there was greater expansion of MP-specific CTLs after booster DCs, relative to
the initial DC injection in all 3 volunteers (Figure 2, a–c). When T cells from
before and after the second immunization were thawed together and cocultured with peptide-pulsed DCs, there
was a greater expansion of MP-specific
IFN-γ–producing T cells after booster
DCs, which correlated with the CTL
data (Figure 2f). As with the ELISPOT
assays in uncultured cells, the increase
in T-cell recall assays after the booster
DCs was not sustained and was followed by a contraction phase similar to
that after the first injection.

Discussion
In this study, we have followed several

aspects of the T-cell response to 2 DC
immunizations in humans. The number of circulating antigen-specific IFNγ–secreting CD8+ T cells is rapidly
enhanced following DC injection and
peaks by 7–30 days after injection. The
measured responses then decline over
the next 3 months. This decline in Tcell reactivity may either be because of
loss of measured function (e.g., the
capacity to secrete cytokines or to proliferate in recall assays) or loss of T
cells because of activation-induced cell
death (AICD) and the rapid disappearance of antigen-bearing DC in vivo.
Persistence of CD8+ T cells may also
depend on the presence of influenzaspecific CD4+ T cells, which are not
induced by MP. These data about the
kinetics of response have important
implications for both the optimal
schedule of immune monitoring and
DC immunizations in clinical trials.
Thus, peak immune responses may
not be manifest until 1–3 months after
the DC injection and frequent (e.g.,
weekly/bimonthly) injections of DCs
may actually be detrimental by inducing AICD of recently activated T cells.
CD4+ T-cell responses to both a priming (KLH) and boosting (TT) antigen
after a single DC injection also involves
a similar rapid increase followed by a

decline. However, these responses
remained detectable above baseline for
≥ 6 months in some subjects. The
observed lack of KLH-specific antibody
response after KLH-pulsed DCs can be
attributed to a lack of free/soluble antigen when delivered with DCs.
In following the kinetics of T-cell
activity using quantitative assays in the
blood of humans after DC immunization, we find that the responses can be
detected without the need to expand
the T cells in vitro before the assay. The
immune responses in humans last several months, in contrast to a recent
study in mice wherein response was evident only in terms of weeks (7).
Recent studies in mice have shown
that CD4+ T cells help the generation
of CD8+ T-cell responses through
CD40 ligand-mediated activation of
DCs (8). Thus, KLH and TT may have
provided help for the generation of
CD8+ T-cell responses after the first
DC injection. Alternatively, mature
DCs may already be activated and
therefore may not require CD4-mediated help, as has been observed in vitro
(9). All 3 subjects rapidly responded to
MP-pulsed mature DCs without KLH
or TT, indicating that these epitopes
are not required for eliciting CD8+ Tcell responses using mature DCs.

Figure 3
MP-specific T cells after booster DCs show greater peptide sensitivity than those after the
first injection. Cryopreserved PBMCs from 30 days after the first (post-1; circles) and second booster antigen-pulsed (post-2; squares) DC injection were thawed together and cocultured with freshly generated mature DCs (DC/PBMC ratio 1:30), pulsed with graded
(0.01–100 ng/mL) MP. After overnight culture, the presence of MP-specific T cells (expressed
as SFCs) was quantified using an ELISPOT. (Top) Effect of peptide dose pulsed on DCs on
the detection of MP-specific IFN-γ–producing cells. (Bottom) Data expressed as percent of
reactivity seen with DCs pulsed with the highest dose of MP (100 ng/mL).
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However, exclusion of these foreign
helper epitozpes does not stringently
exclude CD4 help generated inadvertently during DC culture (10). Ongoing studies will determine if the inclusion of these epitopes alters the
generation of immune response.
Booster DCs led to significantly higher and more rapid T-cell responses,
detectable as early as 2 days after injection. Thus, although all measured
immune responses such as ELISPOT as
well as recall assays using DCs had
returned to baseline before booster DCs,
these subjects had retained “memory”
of the first DC injection at the level of
the whole individual. Therefore,
humans retain a memory for the antigen that was administered on the first
dose of DCs that we are unable to measure with current functional assays.
A more effective form of protective
immunity may be provided by circulating antigen-specific killers. Such
responses have been detected in
humans previously only following
acute viral infections (e.g., acute HIV or
Epstein-Barr virus infection) or certain
live attenuated vaccines (e.g., measles),
but not with subunit vaccines. The
development of circulating lytic effectors in 1 subject after booster DCs in
this study suggests that this may be
feasible by using DCs in humans, particularly when one optimizes variables
such as DC dose, route of administration, maturation status, helper epitopes, and DC survival in vivo.
Another important and novel aspect
of immune response to booster DCs
observed here is the enhanced functional avidity of CD8+ T-cell response,
manifest as greater peptide sensitivity
of T cells elicited after booster DCs.
Similar findings were made independ-
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ently in mice; i.e., T cells elicited during secondary viral infection exhibited
greater peptide sensitivity (11–13). To
our knowledge, this is the first evidence of qualitative enhancement of
T-cell function in humans after a vaccination strategy. Higher-affinity T
cells may be essential to achieve protective immunity against viruses and
tumors in vivo (14, 15). Additional
research will be needed to pursue and
therapeutically exploit the intriguing
potential of DC immunization that is
revealed in the current study. A first
dose of DCs expands effector and
memory T cells, whereas a second dose
elicits more rapid, readily measurable
responses that include lytic effectors
and CD8+ effector T cells with higher
functional avidity.
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